Pfizer Inc. (NYSE:PFE) announced a quarterly dividend on Friday, December 14th, RTT News reports. Stockholders of record on Friday, February 1st will be paid a dividend of 0.36 per share by the biopharmaceutical company on Friday, March 1st. This represents a $1.44 annualized dividend and a dividend yield of 3.45%. The ex-dividend date of this dividend is Thursday, January 31st. This is an increase from Pfizer’s previous quarterly dividend of $0.34.
Pfizer has increased its dividend by an average of 6.7% per year over the last three years and has raised its dividend every year for the last 9 years. Pfizer has a dividend payout ratio of 48.2% meaning its dividend is sufficiently covered by earnings. Research analysts expect Pfizer to earn $2.99 per share next year, which means the company should continue to be able to cover its $1.44 annual dividend with an expected future payout ratio of 48.2%.
Shares of NYSE:PFE opened at $41.70 on Thursday. Pfizer has a one year low of $34.32 and a one year high of $46.47. The firm has a market capitalization of $248.12 billion, a PE ratio of 13.90, a P/E/G ratio of 2.42 and a beta of 0.77. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.15 and a current ratio of 1.43.
Several analysts recently issued reports on PFE shares. Zacks Investment Research lowered shares of Pfizer from a “hold” rating to a “sell” rating in a research report on Friday, January 25th. Credit Suisse Group set a $42.00 price target on Pfizer and gave the company a “hold” rating in a research report on Monday, November 26th. Societe Generale set a $43.00 target price on Pfizer and gave the stock a “hold” rating in a research report on Thursday, November 1st. Cantor Fitzgerald reissued a “buy” rating and issued a $53.00 price target on shares of Pfizer in a research note on Monday, November 19th. Finally, Goldman Sachs Group reaffirmed a “neutral” rating and issued a $45.00 price target on shares of Pfizer in a research report on Tuesday, October 30th. Three equities research analysts have rated the stock with a sell rating, thirteen have given a hold rating and seven have given a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $44.68.
Pfizer announced that its board has authorized a share repurchase program on Friday, December 14th that authorizes the company to buyback $10.00 billion in outstanding shares. This buyback authorization authorizes the biopharmaceutical company to buy up to 3.8% of its shares through open market purchases. Shares buyback programs are typically an indication that the company’s board believes its stock is undervalued.
In related news, EVP Douglas M. Lankler sold 38,800 shares of the company’s stock in a transaction that occurred on Wednesday, January 30th. The stock was sold at an average price of $41.19, for a total transaction of $1,598,172.00. Following the transaction, the executive vice president now directly owns 83,592 shares of the company’s stock, valued at approximately $3,443,154.48. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, EVP Douglas M. Lankler sold 5,000 shares of the firm’s stock in a transaction that occurred on Friday, February 1st. The stock was sold at an average price of $42.75, for a total transaction of $213,750.00. Following the transaction, the executive vice president now directly owns 83,592 shares in the company, valued at $3,573,558. The disclosure for this sale can be found here. Insiders own 0.06% of the company’s stock.
Several large investors have recently made changes to their positions in PFE. 1 North Wealth Services LLC acquired a new stake in shares of Pfizer in the fourth quarter valued at about $40,000. Portfolio Solutions LLC acquired a new position in shares of Pfizer in the fourth quarter worth about $113,000. Essex Investment Management Co. LLC acquired a new stake in Pfizer during the 4th quarter worth approximately $136,000. Spectrum Management Group Inc. boosted its holdings in shares of Pfizer by 8.1% in the fourth quarter. Spectrum Management Group Inc. now owns 4,247 shares of the biopharmaceutical company’s stock valued at $185,000 after acquiring an additional 320 shares in the last quarter. Finally, Lipe & Dalton grew its stake in Pfizer by 28.4% during the fourth quarter. Lipe & Dalton now owns 4,519 shares of the biopharmaceutical company’s stock worth $197,000 after buying an additional 1,000 shares during the period. Institutional investors own 70.61% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Pfizer Inc. (PFE) Announces Quarterly Dividend of $0.36” was first posted by Baseball Daily News and is the property of of Baseball Daily News. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of United States and international trademark & copyright law. The legal version of this piece of content can be read at https://www.baseballdailydigest.com/news/2019/02/14/pfizer-inc-pfe-to-go-ex-dividend-on-january-31st.html.
Pfizer Company Profile
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.